CardioExchange Archive

November 4th, 2012

ASPIRE: Aspirin an Attractive Alternative After First VTE

Larry Husten, PHD

It is unclear what the best approach is for the long-term treatment of people who have had a first unprovoked episode of venous thromboembolism (VTE). Although warfarin is effective at preventing a recurrence, it is inconvenient and raises the risk for bleeding. Newer anticoagulants have not been tested or approved for this population. The ASPIRE (Aspirin […]

---

October 8th, 2012

Triple Antithrombotic Therapy: What — and When — Is the Bleeding Risk?

Morten Lamberts, MD and John Ryan, MD

Morten Lamberts, MD, lead investigator of a recent registry study of various combinations of antithrombotic agents in patients with AF and CAD, answers John Ryan’s questions about the study and its implications.

---

September 6th, 2012

Selections from Richard Lehman’s Literature Review: September 6th

Richard Lehman, BM, BCh, MRCGP

This week’s topics includes studies on aspirin plus clopidogrel in patients with recent lacunar stroke and the risk of coronary events in patients with either CKD or diabetes.

---

August 28th, 2012

Selections from Richard Lehman’s Literature Review: August 28th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include studies on biolimus-eluting stents vs. bare-metal stents, risk markers to improve CV event prediction, common carotid intima-media thickness and CV risk prediction, aspirin with alteplase for acute ischemic stroke, and lipid-lowering therapy (and its benefits and harms) in patients with CKD.

---

August 28th, 2012

WOEST: Get Rid of the Aspirin in Triple Therapy

Larry Husten, PHD

According to current guidelines and clinical practice, PCI patients already taking an oral anticoagulant generally end up on triple therapy comprising the anticoagulant plus clopidogrel and aspirin. However, there is no supporting evidence base for this approach, and the triple-therapy regimen is known to increase bleeding complications. Now a new study — the first randomized […]

---

June 26th, 2012

Aspirin Reduces Risk for Recurrent VTE

John Ryan, MD and ceciliabecattini690

John Ryan interviews Cecelia Beccatini about her new study that found that aspirin treatment in patients with first-time unprovoked VTE resulted in a significant reduction in VTE but did not increase the risk for bleeding.

---

June 6th, 2012

Real-World Bleeding Risk with Aspirin in Primary Prevention Examined

Larry Husten, PHD

A new study published in JAMA provides substantial new evidence about the real-world effects of aspirin, including the risk for  bleeding, in a broad  population. The study also sheds important new light on the effects of aspirin in a diabetic population. Giorgia De Berardis and colleagues analyzed data from more than 4 million people in Puglia, Italy […]

---

May 29th, 2012

Selections from Richard Lehman’s Literature Review: Week of May 28th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include treating obstructive sleep apnea, using aspirin for VTE, and prothrombotics.

---

May 24th, 2012

Aspirin Found to Prevent Recurrent Venous Thromboembolism

Larry Husten, PHD

Aspirin can help prevent the recurrence of venous thromboembolism (VTE) after discontinuation of anticoagulation therapy, according to results of the WARFASA (the Warfarin and Aspirin) study published in the New England Journal of Medicine. Following 6 to 18 months of oral anticoagulation, 403 patients with first-time unprovoked VTE were randomized to aspirin (100 mg daily) or placebo for 2 […]

---

May 21st, 2012

Selections from Richard Lehman’s Literature Review: Week of May 21st

Richard Lehman, BM, BCh, MRCGP

This week’s topics include warfarin vs. aspirin for stroke prevention in HF, CVD risks and azithromycin, coffee’s benefits, the old news that statins work, the question of HDL-C, abdominal aortic aneurysm, omega-3 fatty acid supplements, and Abbott’s methods for staying ahead with fenofibrate prescriptions.

---